{
    "id": "correct_subsidiary_00055_0",
    "rank": 84,
    "data": {
        "url": "https://slideplayer.com/slide/4472609/",
        "read_more_link": "",
        "language": "en",
        "title": "ImmuMed A Therapeutic Antibody Company Corporate Overview JUNE ppt download",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://slideplayer.com/static/blue_design/img/logo_slideplayer.png",
            "https://slideplayer.com/static/blue_design/img/slide-loader4.gif",
            "https://slideplayer.com/slide/4472609/14/images/1/ImmuMed+A+Therapeutic+Antibody+Company+Corporate+Overview+JUNE+2015.jpg",
            "https://slideplayer.com/slide/4472609/14/images/2/Forward-looking+Statements.jpg",
            "https://slideplayer.com/slide/4472609/14/images/3/ImmuMed+Profile+Private+therapeutic+antibody+company.jpg",
            "https://slideplayer.com/slide/4472609/14/images/4/Investment+Thesis+%E2%80%93+ROI+vs+R%26D+process+mitigates+risk.jpg",
            "https://slideplayer.com/slide/4472609/14/images/5/Market+Value+Proposition.jpg",
            "https://slideplayer.com/slide/4472609/14/images/6/Competitive+Landscape+for+Induction+Therapy.jpg",
            "https://slideplayer.com/slide/4472609/14/images/7/Approved+Polyclonal+%26+Monoclonal+Antibodies.jpg",
            "https://slideplayer.com/slide/4472609/14/images/8/Technology+Background.jpg",
            "https://slideplayer.com/slide/4472609/14/images/9/Common+Manufacturing+Platform.jpg",
            "https://slideplayer.com/slide/4472609/14/images/10/Pipeline+Target+Markets.jpg",
            "https://slideplayer.com/slide/4472609/14/images/11/How+Does+IALG+Work+-+Adjuvant+Immunosuppressive+Drug.jpg",
            "https://slideplayer.com/slide/4472609/14/images/12/Clinical+Development+Summary.jpg",
            "https://slideplayer.com/slide/4472609/14/images/13/Phase+III+Trial+Efficacy%3A+Enhanced+Graft+Survival.jpg",
            "https://slideplayer.com/slide/4472609/14/images/14/IALG+vs.+Rabbit+Antithymocyte+Globulin.jpg",
            "https://slideplayer.com/slide/4472609/14/images/15/Renal+Transplant+Patients.jpg",
            "https://slideplayer.com/slide/4472609/14/images/16/Proven+Polyclonal+Market+%28Thymoglobulin%29.jpg",
            "https://slideplayer.com/slide/4472609/14/images/17/Large+Plasma+Inventory+Low+Inventory+Potential+Liquid+Solution+Always.jpg",
            "https://slideplayer.com/slide/4472609/14/images/18/Strong+Intellectual+Property.jpg",
            "https://slideplayer.com/slide/4472609/14/images/19/Multiple+Registration+Plans+Available+for+IALG.jpg",
            "https://slideplayer.com/slide/4472609/14/images/20/FDA+Pathway+%2F+Regulatory+Milestones.jpg",
            "https://slideplayer.com/slide/4472609/14/images/21/IALG+Pro+Forma+vs.+Expected+Global+Market.jpg",
            "https://slideplayer.com/slide/4472609/14/images/22/Business+Objectives+Complete+Market+Approvals+for+IALG.jpg",
            "https://slideplayer.com/slide/4472609/14/images/23/Business+Model+Vision%3A.jpg",
            "https://slideplayer.com/slide/4472609/14/images/24/Mitigation+of+Investment+Risk.jpg",
            "https://slideplayer.com/slide/4472609/14/images/25/Executive+Mgt..jpg",
            "https://slideplayer.com/slide/4472609/14/images/26/Advisors.jpg",
            "https://slideplayer.com/slide/4472609/14/images/27/Investment+Thesis+%E2%80%93+ROI+vs+R%26D+process+mitigates+risk.jpg",
            "https://slideplayer.com/1/242080/big_thumb.jpg",
            "https://slideplayer.com/4/1445755/big_thumb.jpg",
            "https://slideplayer.com/10/2752269/big_thumb.jpg",
            "https://slideplayer.com/11/3258687/big_thumb.jpg",
            "https://slideplayer.com/11/3259354/big_thumb.jpg",
            "https://slideplayer.com/11/3332491/big_thumb.jpg",
            "https://slideplayer.com/12/3462108/big_thumb.jpg",
            "https://slideplayer.com/12/3532534/big_thumb.jpg",
            "https://slideplayer.com/13/3822191/big_thumb.jpg",
            "https://slideplayer.com/13/3856623/big_thumb.jpg",
            "https://slideplayer.com/13/3872496/big_thumb.jpg",
            "https://slideplayer.com/13/3902124/big_thumb.jpg",
            "https://slideplayer.com/14/4372565/big_thumb.jpg",
            "https://slideplayer.com/14/4430338/big_thumb.jpg",
            "https://slideplayer.com/15/4732274/big_thumb.jpg",
            "https://slideplayer.com/16/4896943/big_thumb.jpg",
            "https://slideplayer.com/16/4949834/big_thumb.jpg",
            "https://slideplayer.com/16/4974941/big_thumb.jpg",
            "https://slideplayer.com/16/5221050/big_thumb.jpg",
            "https://slideplayer.com/17/5345511/big_thumb.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "ImmuMed A Therapeutic Antibody Company Corporate Overview JUNE 2015"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Forward-looking Statements This presentation contains statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of Such forward-looking statements involve known and unknown risks, uncertainties, and other facts, which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  When used in this presentation, statements that are not statements of current or historical fact may be deemed to be forward-looking statements.  Without limiting the foregoing, the words “plan,” “intended,” “may,” “expect,” “believe,” “could”, “anticipate,” “estimate,”  or “continue” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  Except as required by law, the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Information, in part, contained herein has been excerpted from an Investigational New Drug Exemption (IND) sponsored by the Company and is considered the intellectual property of the author and sponsor, and constitutes confidential information within the meaning of the Federal Food, Drug and Cosmetic Act (21USC331U[j]), the Freedom of Information Act (5USC1002) or the Trade Secrets Act (18USC1905) and may not be revealed or disclosed to any party, nor may be reproduced or copied in any form or by any means, - graphic, electronic, or mechanical, including photocopying, taping or information storage and retrieval without the written authorization of ImmuMed, Inc. This document does not constitute an offer to sell or a solicitation to purchase anything whatsoever.  Neither this document nor any of its content may be disclosed to any person under any circumstances without the express written permission of ImmuMed, Inc. ImmuMed  Inc.© Confidential",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://slideplayer.com/slide/4472609/",
        "text": "Presentation on theme: \"ImmuMed A Therapeutic Antibody Company Corporate Overview JUNE 2015\"— Presentation transcript:\n\n1 ImmuMed A Therapeutic Antibody Company Corporate Overview JUNE 2015\n\nPrivate and Confidential ImmuMed Inc.© Confidential\n\n2 Forward-looking Statements\n\nThis presentation contains statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of Such forward-looking statements involve known and unknown risks, uncertainties, and other facts, which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. When used in this presentation, statements that are not statements of current or historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “plan,” “intended,” “may,” “expect,” “believe,” “could”, “anticipate,” “estimate,” or “continue” or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Information, in part, contained herein has been excerpted from an Investigational New Drug Exemption (IND) sponsored by the Company and is considered the intellectual property of the author and sponsor, and constitutes confidential information within the meaning of the Federal Food, Drug and Cosmetic Act (21USC331U[j]), the Freedom of Information Act (5USC1002) or the Trade Secrets Act (18USC1905) and may not be revealed or disclosed to any party, nor may be reproduced or copied in any form or by any means, - graphic, electronic, or mechanical, including photocopying, taping or information storage and retrieval without the written authorization of ImmuMed, Inc. This document does not constitute an offer to sell or a solicitation to purchase anything whatsoever. Neither this document nor any of its content may be disclosed to any person under any circumstances without the express written permission of ImmuMed, Inc. ImmuMed Inc.© Confidential\n\n3 ImmuMed Profile Private therapeutic antibody company\n\nMission: To utilize our proprietary therapeutic antibody platform and build a leading organ transplantation business and transform the field by expanding recipient eligibility and enabling universal organ donor transplants Established Lead product: Anti-Lymphocyte Globulin (ALG) Historical use in 52,000 in organ transplant recipients at over 281 transplant centers across the U.S., Canada and parts of Europe Primary indication: Induction Therapy (Prevention of Acute Rejection) Published scientific record of efficacy and safety, support from KOLs in transplant Antibody Platform and Pipeline Portfolio targeting antibody markets > $3B ImmuMed Inc.© Confidential\n\n4 Investment Thesis – ROI vs R&D process mitigates risk\n\nInitial transplant antibody market size estimated at $470M W/W 85% of revenue earned from Induction Therapy ** Opportunity to revive proven product used in over 52,000 patients Task: update mfg. and reproduce historical tox data to satisfy FDA IND requirement $30M investment to market-rollout first product $10M to kick-off Ph III and potential IPO Projected $250M+ in revenue within 5 years Competitor with $79M in revenue sold for $600M in 2003 (8X multiple) Additional revenue from pipeline development funded by product sales ** Induction Therapy is a drug protocol employing the administration of therapeutic antibodies to prevent rejection immediately following organ transplantation ImmuMed Inc.© Confidential\n\n5 Market Value Proposition\n\nGrowing organ transplantation industry Increasing demand for organ transplants (W/W) Global Shortage of Donor Organs (growing waiting lists) Increasing Use of High-Risk Donor Organs (must use polyclonal antibody) Fragmented market without a clear leader Multiple products are sold into the field on a fragmented basis Clear unmet transplantation medical need No product enables universal organ donation No polyclonal antibody currently licensed for induction therapy No product addresses sensitized recipients Key anti-rejection products are marginally effective or sold “off-label” ImmuMed well positioned for: Market expansion by enabling universal organ transplants Capture the sales of current products now being used off-label Consolidation of existing products and businesses Market leadership to Establish Induction Therapy as Standard of Care ImmuMed Inc.© Confidential\n\n6 Competitive Landscape for Induction Therapy\n\nAntibody-based Immunosuppressive Drugs Monoclonal Antibodies (Low Risk Recipients) 5% US Revenue Share Single antigenic site with high specificity Two (Simulect,® Zenapax®) approved to prevent rejection One (OKT3) approved to treat acute rejection Polyclonal Antibodies (High Risk Recipients) Multiple antigenic sites – cytotoxic activity None approved for prevention of rejection Two approved (Thymoglobulin® , Atgam®) to treat acute rejection Treatment of Acute Rejection by antibodies – occurs in 4% of transplants Antibody revenues (Induction Therapy) now driven by Off-Label Use See IALG advantages vs. Thymoglobulin More efficient production at higher margins Absence of 10% microaggregates  less safety concerns 95% US Revenue Share ImmuMed Inc.© Confidential\n\n7 Approved Polyclonal & Monoclonal Antibodies\n\n2012 Global Antibody Sales Approved Polyclonal & Monoclonal Antibodies Product Name Type of Product Manufacturer Indication $$ Sales ($Millions) % Change vs. PY Thymoglobulin® (Rabbit) Polyclonal Genzyme Rx AR $320 12.0 % Simulect® (Murine) Monoclonal Novartis Induction $110 4.5 % rATG * Fresenius $ 40 8.0 % * Not sold in U.S. Source: Evaluate Pharma 2013 ImmuMed Inc.© Confidential\n\n8 Technology Background\n\nTherapeutic antibody technology acquired from U. Minnesota 1996 $66M R&D investment already done Lead product: ImmuMed Anti-Lymphocyte Globulin (“IALG”) Primary indication: prevent rejection after solid organ transplantation 52,000 patient administrations (Compassionate Use) at least 281 transplant centers across the U.S., Canada and parts of Europe Lack of sufficient data reporting on compassionate use caused FDA clinical hold University refused commercial drug production FDA issue with original inventor resolved Multiple pipeline products from common plasma inventory Precondition donor tissue for bone marrow and stem cell transplants Aplastic anemia Autoimmune diseases Lymphomas (FAB2 form) Qualified strategic partners identified CMO: Cangene and/or Therapure BioPharmaceutical CSO: Bio-Reliance and Apptec CSO: Lake Immunogenics CRO: Cato Research; Kendle; CTI ImmuMed Inc.© Confidential\n\n9 Common Manufacturing Platform\n\nPipeline Common Manufacturing Platform Program Indication R&D PC Phase I Phase II Phase III Biological Antibodies ALG Solid Organ Transplantation IATG-BMT Bone Marrow Transplantation H. anti HIV Adjuvant Therapy in HIV and AIDS Recombinant Antibodies Fab 2 Infectious Diseases ISI Mab Cancer Immunotherapy Additional Opportunities PRODUCT PIPELINE ** ** Of products in its portfolio, ImmuMed has prioritized the sequence in which to develop acquired compounds based on the current stage of clinical development listed below. ImmuMed Inc.© Confidential\n\n10 Pipeline Target Markets\n\nLead product: ImmuMed Anti-Lymphocyte Globulin (“IALG”) $470MM potential market oppty. based on existing drugs Target markets for follow on pipeline products (derivatives of common plasma inventory = truncated development pathway) Graft versus Host disease in Bone Marrow Transplant ($80MM) Aplastic Anemia ($175MM) Reduced viral loads in CMV and HIV infected patients ($750MM) B-cell lymphoma ($30MM) B-Cell Mediated Auto-Immune Diseases ($125MM) IVIG ($1.4B) ImmuMed Inc.© Confidential\n\n11 How Does IALG Work? - Adjuvant Immunosuppressive Drug\n\n- Mechanism of Action - Degraded by Liver Adjuvant = administration as add-on to background immunosuppressive regimens to improve outcomes Cytotoxic to lymphocytes (including those causing acute organ rejection ) Decreases: Recognition of Foreign Antigen Incidence of Acute Rejection Incidenceof Post-op dialysis events Anti-IALG antibodies occasionally measured ImmuMed Inc.© Confidential\n\n12 Clinical Development Summary\n\nPublished Scientific Studies Human Studies Sample Size Major Findings Phase I (1) Pharmacokinetics (N = 104) Depletion Circulating lymphocytes Phase II (2) Dose response in humans a) Skin grafts (N = 102) b) Renal grafts (N = 47) Increased graft survival was dose related Phase III (3) Study drug v. Placebo Renal grafts (N = 160) Therapeutic Benefit improved renal graft survival at 1 & 3 years ** No Safety Issues ** 1) Buchman TE., et al; Transplantation. 55(5):1190‑3, 1993 May. 2) Simmons RL. Moberg AW., et al: Surgery. 68(1):62‑8, 1970 Jul. 3) Condie RM, et al, Transplantation proceeding 1985; XVII(1): ImmuMed Inc.© Confidential\n\n13 Phase III Trial Efficacy: Enhanced Graft Survival\n\nPost-Transplant Event ALG (n=81) Albumin (n=79) P-Value Graft Survival: 3 years 45/81 (56%) 18/79 (23%) p<0.015 Graft Survival: 1 year 48/81 (59%) 37/79 (47%) p = 0.02 First rejection episode (median) 28 days 11 days p<0.0001 Fever 24.7% 15.2% NS Chills 13.6% 6.3% Hematuria 11.1% 13.9% Nausea 7.4% 2.5% Infections 49.4% 55.7% ALG versus Placebo (Phase III study) Multicenter Efficacy Study for Induction Therapy Efficacy Safety ImmuMed Inc.© Confidential\n\n14 IALG vs. Rabbit Antithymocyte Globulin\n\nComparative Performance Equine vs. Rabbit IALG vs. Rabbit Antithymocyte Globulin [Comparative Efficacy for Induction Immunosuppression] Univ Hospital of Cincinnati Cincinnati, OH + 4 other hospitals ALG (n=48) 50 (24) % Patient Survival 6 months 12 months % Graft Survival % Patients with Rejection Serum Creatinine (mean) rATG (n=50) 60 (30) p value NS ImmuMed Inc.© Confidential\n\n15 Renal Transplant Patients\n\nIALG: Favorable Sample Size and AE/SAE Rates Renal Transplant Patients ALG(1) Atgam(2) OKT3(2) Thymoglobulin(2) Simulect(2) Safety Database 8,059 1,587 63 82 193 Incidence of Death 0.5% 28.0% 4.7% 7.3% 4.6% ALG data derived from all of the Case Report Forms submitted by transplant centers utilizing ALG in response to a letter request from the University of Minnesota pursuant to the clinical hold imposed by FDA. They represent data from all of the renal transplant patients from December 28, 1988 to August 12, 1992. Data from FDA’s summary basis of approval. ImmuMed Inc.© Confidential\n\n16 Proven Polyclonal Market (Thymoglobulin)\n\nSales and Market valuation of Thymoglobulin have soared due to: Off-label use Absence of competitors 1980 Pasteur Merioux (France) Product: Lymphoglobuline in EU 1993 Sangstat (California) Licensed Lymphoglobuline, N.A. Renames: Thymoglobulin Q3 – Sangstat IPO @ $7.50 per share Piper lead, H&Q, others 1997 1998 Q4 – Sangstat Acquires Thymoglobulin From Pasteur Merioux: 2003 Q3 – Genzyme Acquires Sangstat $31M $600M Q1 – Sangstat Secondary Offering @ $30 share, 2.6 M shares H&Q lead, others History 2008 $198M 17.8% 18.7% 18.5% Sales 2005 $128M 2004 $108M 2003 $91M 2006 $156M 21.9% 2007 $168M 11.5% 2009 $232M 2010 $250M 17.2% 7.1% 2012 $320 M ** Sales to 2010 derived from 10Q filings; since Sanofi purchase current sales (2012) independent estimate ImmuMed Inc.© Confidential\n\n17 Large Plasma Inventory Low Inventory Potential Liquid Solution Always\n\nIALG Competitive Advantages IALG Thymoglobulin ImmuMed Sanofi Efficiency 1 Horse = 140 liters 2,800 Rabbits = 140 liters Mfg. Volumes Large Plasma Inventory Low Inventory Potential Production Powder-Freeze Dried Physical State Liquid Solution Always Gross Margins Fraction of MALG High Market Factors Safety & Efficacy T-Cell B-Cell Antigen Type T-Cell Only Purity 90% 99% <1% Micro-aggregates 10% ImmuMed Inc.© Confidential\n\n18 Strong Intellectual Property\n\nIALG ADVANTAGE Proprietary Patentable Essential to Developing Biologic Activity Essential to Not Destroying Biologic Activity Newly Formulated Plasma Purification Process Immunogens T-cells B-cell (available only for IALG) Method of Immunization New Patent Method of Lot Formulation Proprietary + Data + New Patent Claims = Unique Phase 3 Product ImmuMed Inc.© Confidential\n\n19 Multiple Registration Plans Available for IALG\n\nPivotal Trial Options Available US Trial Potentials Label NIT to Standard of Care Induction Label NIT to Simulect or Zenapax Induction Label Superiority to Simulect or Zenapax Induction Label NIT to Atgam or Thymoglobulin Rejection Treatment Differential Dosing (high/low IALG dose) Induction Label Non-US Trial Potentials Study drug vs. Placebo; Induction Protocol Superiority to Simulect or Zenapax NIT to Simulect or Zenapax; Induction Protocol Current Status: No Approved Polyclonal Standard of Care for Induction ImmuMed Inc.© Confidential\n\n20 FDA Pathway / Regulatory Milestones\n\nMarketing approval for a large molecule biologic based on standardized method of manufacturing correlated with safety and therapeutic benefit data discovered pursuant to a pivotal clinical trial. Based on Pre-IND Meetings, ImmuMed required to: Finalize manufacturing method (finished by vendor) Manufacture commercial size lots (sufficient for 2,400 patients) Repeat toxicity study (required for new manufacturing process) Submit new IND for IALG pivotal clinical trial (drafted) Complete nested dosing and pivotal trial File BLA using new acquired data ImmuMed Inc.© Confidential\n\n21 IALG Pro Forma vs. Expected Global Market\n\nIALG Revenue Model IALG Pro Forma vs. Expected Global Market (5% Projected Growth) Funding Pro Forma Global ImmuMed Inc.© Confidential\n\n22 Business Objectives Complete Market Approvals for IALG\n\nInduction Therapy Indication Ph IV study for chronic rejection (3 and 5 year end-points) Expand life-cycle for desensitization therapy Early Market Exposure and Revenues Secondary Retransplant Market in US – (≈ 2,000 / year) “Named-Patient” sales – EU and rest of world (ROW) Emergency drug release authorization (Canada) Product Launches First on-label product in induction therapy(≈ 36 months) Capture “Off-Label sales; gain market share from monoclonals First product for desensitization (if studied) Consolidate products/market as single industry leader ImmuMed Inc.© Confidential\n\n23 Business Model Vision:\n\nBegin As Near Virtual Company during pre-revenue period Minimal Infrastructure, Rely On Outsourcing Avoid Amassing Overhead In Search of Products Commercialize Established Polyclonal Antibodies First Focus On Achieving Early Cash Flow Projected 12 to 15 Months No Early R & D Expense Build Infrastructure, R & D With Cash Flow Expand Acquired Portfolio; In-License or Acquire New Technologies Execution: Build the ImmuMed Company Restart IALG Production FDA Phase III IND #1 Sales Strategic Alliances for Distribution R&D Outsourcing Co-Develop IPO Acquired Merge O U T S R C E Material Prod Testing Trials ImmuMed Inc.© Confidential\n\n24 Mitigation of Investment Risk\n\nReduced Regulatory & Development Risk Multiple, well-defined FDA pathways (5 previous antibody products) No R & D required absence of surprises, efficacy understood 52,000 patient history to supplement new safety data Efficacy and superiority established Data points (safety, dose, efficacy) to be replicated, not new Manufacturing method establish/approved for another product type Proven Mfg. partners with experience in existing products Attractive Commercial Opportunities Growing transplant market Product history demonstrates high medical approval Acceptance of safety and efficacy profile Multiple products derived from the same manufacturing platform High manufacturing COG margins Transplant market is mature, yet highly focused Only few dozen leading US transplant centers potentiates “80:20” market scenario. ImmuMed Inc.© Confidential\n\n25 Executive Mgt. Martin Driscoll, Chairman of the Board of Directors - Presently CEO and Director of Asmacure Ltee, a venture-backed clinical-stage biopharmaceutical company. Previous CEO of Javelin Pharmaceuticals (acquired by Hospira, Inc. in 2010). Over 31 years’ experience in bio pharmaceutical industry with responsibility in commercial, business development, and general management at Schering-Plough, ViroPharma, and Reliant Pharmaceuticals. Allen Moberg, MD., Acting CEO/Director/CMO - Founder of ImmuMed, Inc.. Received his MD degree in 1964 and thereafter was educated in general and transplantation surgery at the University of Minnesota. Was responsible for development and patenting of medical devices for organ preservation and cofounder of IALG Program with other colleagues in the University of Minnesota’s Department of Surgery. Served as initial Program Director responsible for IALG’s production, Phase I and Phase II clinical testing, coa-uthored IND. Recent focus on organizing effort to return IALG to the marketplace, including raw material production and manufacturing and regulatory affairs. Thomas Burton, CFO/Director - Cofounder of ImmuMed. From 1960 to 1990, was President and CEO of Waters Instruments, Inc., a diversified publicly traded company [ZRBA-NASDAQ] manufacturing and marketing medical and electronic devices. Served by appointment by the Governor of Minnesota on the Public Utilities Commission. Recently consulting with principal investigators developing new products in the medical field. ImmuMed Inc.© Confidential\n\n26 Advisors Peter Levitch - Special expertise in clinical study design, implementation and compliance, good manufacturing practices and regulatory affairs. 25 years as consultant to more than 200 biotech, pharmaceutical and medical device companies, participating in at least 260 IND’s and FDA approval of many biotechnology derived products. Previous Manager of Clinical Research at Eaton Laboratories and Director of Clinical Research and Regulatory Affairs at Ortho Diagnostics, where, acting as Responsible Head to CBER (working to assure compliance for Ortho’s 60 licensed products) and as Official Correspondent to CMDRH. Thomas Stagnaro – Over 35 years’ experience in medical and biotechnology fields. Presently President, CEO and Founder of Americas Biotech Distributor, LLC., distributing US biotech products into Latin America. Previously President and CEO of Agile Therapeutics, Inc. Prior to Agile, pharmaceutical consultant to Rock Hill Ventures/Hillman Medical Ventures, and President and CEO of 3-Dimensional Pharmaceuticals, Inc. Former Senior Executive Vice President at NABI, responsible for sales and marketing, generating sales in excess of $250 million and served as in the research and development for human polyclonal antibody products and vaccines. At NABI, managed the “In-licensing” of a late-stage product, and successfully brought the product through CBER and launched in US. Prior to NABI, was President and CEO of Univax Biologics, Inc., (acquired by NABI in 1995 for $150 million). John St. Cyr, II, MD, Ph.D. - Director of Research. Surgical education at University of Minnesota, cardiovascular-thoracic training at University of Colorado Health Sciences, specializing in adult and pediatric Cardiovascular surgery, and transplantation. History in research, dedicated to myocardial preservation. ImmuMed Inc.© Confidential"
    }
}